Peptides
Mechanisms, research, benefits, limitations, and emerging applications.
59 articles in Peptides
GLP-1 vs Growth-Hormone Peptides: Different Goals, Different Evidence
Two peptide categories often lumped together — and the wildly different levels of proof behind each.
Read →Injection Technique and Peptides: What the Research Suggests
Site, depth, and rotation shape both safety and absorption — but the evidence comes from insulin, not peptides.
Read →The Economics of Peptide Research: Why Trials Lag
Pivotal trials cost millions and patents fund them. Unpatentable peptides break that model — which explains the evidence gap.
Read →Bioregulator Peptides and Aging: A Skeptical Review
Decades of work from a single Russian institute, almost no independent Western trials, and sweeping longevity claims.
Read →Peptide Tolerance and Desensitization, Explained
GPCR desensitization and downregulation are textbook biology. How strongly they apply to any specific peptide protocol in humans usually isn't.
Read →BPC-157: Separating the Evidence from the Hype
BPC-157 has a large animal-research base and almost no human trial data. A 2025 systematic review found just one human study among 36. Both things are true.
Read →Tesofensine: Appetite, Weight, and the Open Questions
A triple-reuptake inhibitor whose striking phase 2 weight loss is shadowed by safety signals and a Lancet expression of concern.
Read →What Phase a Peptide Is In, and Why It Matters
Preclinical, Phase 1, Phase 3 — the single most useful question to ask about any compound.
Read →How Peptides Signal: Receptors, Cascades, and Effects
From receptor binding to second messengers to effect — the chain of events behind every peptide claim.
Read →Peptides and Cancer Risk: Untangling a Complicated Question
Growth-signaling peptides raise legitimate questions the marketing rarely addresses. Here is what the IGF-1 evidence actually shows.
Read →The Real Risks of Sourcing Peptides Online
Impurities, immunogenicity, and unverifiable purity claims — the FDA-flagged dangers beyond the biology.
Read →Why Peptide Dosing in Studies Rarely Matches Marketing
The doses in the research and the doses on the label are often worlds apart.
Read →Adipotide: A Cautionary Tale in Peptide Development
A fat-loss peptide that shrank monkeys 11% in 28 days — and then failed human trials on kidney safety.
Read →Humanin: A Mitochondrial-Derived Peptide Worth Watching
A mitochondrial peptide ~3x higher in centenarians' offspring — with real biology but no human trials yet.
Read →Growth Hormone Secretagogues: Do They Beat Direct HGH?
Secretagogues raise GH pulses 70-100% but leave serum GH far below injected levels — with thin outcome data.
Read →SS-31 (Elamipretide): The Mitochondrial Peptide in Trials
A genuinely investigational compound that has run real clinical trials — and largely missed its primary endpoints. A useful benchmark.
Read →Compounded Peptides and the FDA's Shifting Stance
The FDA's 503A bulk-substance categories keep moving under compounded peptides like BPC-157.
Read →5-Amino-1MQ: NNMT Inhibition and the Hype Cycle
A metabolic target with real rodent data, a clean mechanism, and zero published human efficacy trials.
Read →Peptides for Skin: Topical vs Injected Evidence
Where cosmetic peptides have a real, modest case, and where injectable claims sprint past the data.
Read →LL-37: The Antimicrobial Peptide Behind the Buzz
A real part of human immunity — and one implicated in autoimmune disease, marketed in ways the evidence doesn't support.
Read →Creatine vs Peptides for Recovery: Where the Evidence Stands
One is among the most-studied supplements ever; the others mostly aren't. The contrast is instructive.
Read →The Placebo Problem in Peptide Research
Placebos produce measurable effects even when patients know they're inert — which is why peptide anecdotes can't be trusted.
Read →Collagen Peptides: One of the Few With Decent Human Data
An outlier in the peptide world — modest skin and joint evidence, with funding and quality caveats.
Read →Peptide Stacking: Why Combining Compounds Multiplies Unknowns
Even approved peptides carry combination warnings. Stacking gray-market compounds adds untested interaction risk on top of thin single-compound data.
Read →BPC-157 and Gut Health: A Closer Look at the Claims
BPC-157's gut data is its strongest — but it is almost entirely rodent work, with no controlled human trials.
Read →Hexarelin: The Forgotten Growth-Hormone Peptide
A potent GH secretagogue sidelined by tachyphylaxis and its cortisol and prolactin release — and what it taught the field.
Read →GHRP-6 vs GHRP-2: Comparing the Older Secretagogues
The first-generation GH peptides, their shared hormonal quirks, and why newer options often replaced them.
Read →BPC-157 for Tendons: What the Animal Studies Found
Reproduced rodent tendon results, essentially no controlled human trials. The honest state of the evidence.
Read →Reconstitution and Storage: The Science of Peptide Stability
Why handling matters, what degrades a peptide, and how that quietly changes whatever you're measuring.
Read →Receptor Agonists vs Antagonists: A Plain-Language Primer
The vocabulary you need to actually understand how a peptide is supposed to act.
Read →Peptide Side Effects: What the Safety Data Actually Shows
GLP-1 drugs have GI side effects in ~73% of users and a boxed thyroid warning. Gray-market peptides have almost no safety data at all.
Read →Why Most Peptide Claims Outrun the Evidence
The structural reasons the marketing is always years ahead of the science.
Read →Are Peptides Legal? The Regulatory Landscape in 2026
Approved drugs, a narrowing compounding lane, and a gray market built on a labeling loophole — explained.
Read →The Difference Between Peptides and Proteins, Explained
Where one ends and the other begins — a soft, roughly 50-residue convention, not a hard chemical line.
Read →Research Peptides and Purity: What 'For Research Use Only' Means
The RUO label isn't a marketing quirk — it's an FDA-defined signal about what testing and oversight you are not getting.
Read →Peptide Half-Life, Explained: Why Dosing Frequency Varies
Native GLP-1 lasts ~2 minutes; semaglutide lasts ~1 week. Half-life is the hidden variable behind every dosing schedule.
Read →Animal Data vs Human Data: The Peptide Translation Gap
Over 92% of drugs that work in animals fail in humans. Here's why peptide rodent data rarely translates.
Read →Oral vs Injectable Peptides: Why the Route Matters
Oral semaglutide has under 1% bioavailability and needs an absorption enhancer. The delivery route can decide whether a peptide works at all.
Read →How to Read a Peptide Study Without Getting Fooled
Fewer than 8% of animal-model drugs survive human trials. A practical filter for reading peptide studies.
Read →Kisspeptin: The Peptide Reshaping Reproductive Research
A genuine area of active clinical science — kisspeptin-54 has triggered egg maturation and live births in IVF trials.
Read →Peptide Bioregulators: Evidence or Marketing?
Khavinson peptides promise organ-specific rejuvenation. After 40+ years, the evidence is mostly cell and animal data with no Western randomized trials.
Read →Follistatin and Muscle Growth: What the Science Says
Blocking myostatin sounds like a shortcut to muscle. The human trials tell a more sobering story.
Read →AOD-9604: The Fat-Loss Peptide That Didn't Pan Out
A growth-hormone fragment trialed for obesity in 500+ adults. The Phase IIb result is the part marketing omits.
Read →How Peptides Are Absorbed: The Bioavailability Problem
Why most peptides are injected, why oral versions are hard, and what oral semaglutide's ~1% bioavailability really shows.
Read →MOTS-c: The Mitochondrial Peptide, Explained
A mitochondrial-derived peptide with striking effects in mice — and only thin, indirect human data.
Read →DSIP (Delta Sleep-Inducing Peptide): Does It Help Sleep?
Named for what it was supposed to do. Decades later, the human sleep evidence remains thin and conflicting.
Read →Epitalon: Sorting the Longevity Claims From the Evidence
A telomere-and-lifespan peptide resting almost entirely on small studies from a single Russian research lineage.
Read →Semax: Nootropic Peptide or Overstated Hype?
Marketed for focus and neuroprotection, Semax has a real research history — mostly outside Western journals and unproven in healthy people.
Read →Selank and Anxiety: A Look at the Limited Human Data
A Russian-developed anxiolytic peptide with real clinical use there and very little independent replication.
Read →Melanotan II: Why the Tanning Peptide Carries Real Risks
The injectable 'tan jab' is unapproved, broadly active, and linked to mole changes and melanoma in case reports.
Read →PT-141 (Bremelanotide): The Evidence on Libido and Arousal
An FDA-approved drug for low desire in premenopausal women — and a popular off-label experiment. What the trials actually show.
Read →Thymosin Beta-4 and Tissue Repair: Reading the Preclinical Data
The molecule behind TB-500 shows real promise in animals. Translating that to humans is the unfinished work.
Read →Tesamorelin: The One Peptide With Real FDA Approval
Approved in 2010 for HIV-associated lipodystrophy, tesamorelin is a rare peptide with genuine phase 3 trial backing.
Read →Thymosin Alpha-1: What We Know About the Immune Peptide
Approved in 35+ countries as thymalfasin, with a real clinical record in hepatitis and sepsis — but not FDA-approved, and the evidence is mixed.
Read →TB-500: What the Research Does and Doesn't Show
Thymosin beta-4's fragment is sold for recovery. The preclinical signal is real; human evidence for athletic recovery is absent — and it's banned in sport.
Read →Ipamorelin: A Closer Look at the Growth-Hormone Secretagogue
A selective GH secretagogue with clean preclinical pharmacology — but no long-term human outcome data.
Read →CJC-1295 and Ipamorelin: How the Combo Is Supposed to Work
Why these two growth-hormone secretagogues are stacked, and what the evidence does and doesn't support.
Read →GHK-Cu: The Copper Peptide Behind the Skin Claims
GHK-Cu has more credible topical evidence than most peptides — and far thinner support for the systemic claims.
Read →Sermorelin vs CJC-1295: Comparing Two GH Secretagogues
Both nudge your own growth hormone. The difference is half-life, dosing, and how much human evidence actually exists.
Read →